Last weekend, I uploaded a blog post that included this graphic describing success and said that it really resonated with me. Back in the day, I was the first employee of Quintessence and have been in my fair share of swirls in our efforts to build the company and move our cancer drug forward. One
I want to share three themes that struck me from the Dohmen Life Science Services Entrepreneur Summit in Milwaukee this week. Is there an age or stage of company that doesn’t require innovation? Dohmen started as an apothecary in 1858 and is a private fifth generation company, which has reinvented itself over the last few years.
Pharma/Biotech Business Model Innovation When I hear/read about business model innovation in pharma/biotech, the themes generally focus on changes that would improve R&D productivity – moving discoveries from academia to industry more efficiently (some examples of university-related incubators), reproducibility of experiments, venture capital firms creating their own early stage companies, pharma moving R&D innovation external (corporate, biotech and
Yesterday on Twitter I asked the following question and I wanted to follow up because it is an interesting topic. Flip but serious: what is lean startup/incubator/hacker version of a university lab? There is a lot of discussion about funding sources for science/biotechnology as pressure increases on some of the traditional pools of money. Yesterday David Shaywitz shared
Today Sandoz announced that their Biologics License Application for filgrastim was accepted by the FDA. This news is significant in part because Zarzio (the brand name for this new product) is the first product to use the 351(k) pathway for biosimilars in the US (rather than the traditional 351(a) BLA). In contrast, there are a
This weekend I came across a blog post “CGM in the Cloud: Personal Preferences” written by Kerri, a woman with Type I diabetes. Her post goes through the factors that resulted in her decision to share her continuous glucose monitoring (CGM) data in the cloud. As I went back in the Six Until Me archives,
In a post in March, I suggested that I would represent the “less glamorous side of things” in the biotech industry. This week gave me an opportunity to attempt that directly. Setting the Stage Earlier this year, Bruce Booth at Atlas Venture started a new thing – a great thing: having management from their biotech portfolio companies
Reflecting on the American Society of Clinical Oncology annual meeting, I’m left thinking about the importance of people despite the vast amounts of data presented. Cancer drug development is a story whose characters are people, not molecules, not data. The ultimate goal is to help people with cancer (patients) but people are at the center
There were a few long reads that I’ll be re-reading over the weekend, including: New blood (at Fortune, by Roger Parloff @rparloff) This article profiles the blood diagnostics company, Theranos, and the founder, Elizabeth Holmes. While you will find the founder description interesting, I found myself drawn to the questions of business model, trade secrets and regulation.
Risk Distribution In WIRED, “One Startup’s Struggle to Survive the Silicon Valley Gold Rush” by Gideon Lewis-Kraus is a very long read for a magazine article but works to compare/contrast the social and economic lives of tech startup founders and employees at larger tech companies. Here’s a passage that stuck with me for hours after reading the